Evaluation of changes in immune system of operating room personnel by measurement of urinary neopterin concentrations

Pteridines

Volumn 22, Issue 1, 2011, Pages 13-17

  Baydar, Mustafa ^a   Capan, Zeynep ^a   Girgin, Gozde ^b   Baydar, Terken ^b   Sahin, Gonul ^b  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Neopterin; Operating room personnel

Indexed keywords

NEOPTERIN;

ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CREATININE URINE LEVEL; ENVIRONMENTAL EXPOSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNE SYSTEM; MACROPHAGE; MALE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; OCCUPATIONAL SAFETY; OPERATING ROOM PERSONNEL; PRIORITY JOURNAL; URINALYSIS; WORKING TIME;

EID: 79957504269     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2011.22.1.13     Document Type: Article

References (22)

1. Occupational medicine-Interface with toxicology, Chapter 16, in Occupational Toxicology, W.O. Phoon, Neil H. Stacey (eds). Taylor and Francis, London, 1995, 295-304.
2. Thorne Ps, Occupational Toxicology, Chapter 33, in Casarett and Doull's Toxicology: The Basic Science of Poisons, CD Klaassen (ed). 6th edition, McGraw-Hill Companies, Inc., 2001, 1123-1140.
3. Gruber G, Lirk P, Amann A, Keller C, Schobersberger W, Hoffmann G, Fuchs D, Rieder J. Neopterin as a marker of immunostimulation: an investigation in anaesthetic workplaces. Anaesthesia 2002; 57: 747-750.
4. Irwin MG, Trinh T, Yao CL. Occupational exposure to anaesthetic gases: a role for TIVA. Expert Opin Drug Saf 2009; 8 (4): 473-483.
5. Byhahn C, Wilke HJ, Westphal K. Occupational exposure to volatile anaesthetics: epidemiology and approaches to reducing the problem. CNS Drugs 2001; 15 (3): 197-215.
6. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307-341.
7. Wirleitner B, Reider D, Ebner S, Guenther B, Widner B, Jaeger M, Schennach H, Romani N, Fuchs D. Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 2002; 72: 1148-1153.
8. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferongamma. J Exp Med 1984; 160: 310-316.
9. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler 1989; 370: 1063-1069.
10. Widner B, Wirleitner B, Baier-Bitterlich G, Weiss G, Fuchs D. Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch Immunol Ther Exp (Warsz) 2000; 48: 251-258.
11. Baydar T, Yuksel O, Sahin TT, Dikmen K, Girgin G, Sipahi H, Kurukahvecioglu O, Bostanci H, Sare M. Neopterin as a prognostic biomarker in intensive care unit patients. J Crit Care 2009; 24: 318-321.
12. Sahin TT, Yuksel O, Sipahi H, Girgin G, Dikmen K, Azili C, Taneri F, Baydar T. Urinary neopterin in patients with thyroid disorders. J Endocrinol Invest 2009; 32 (2): 147-149.
13. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26: 319-329.
14. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187.
15. Ruokonen E, Ilkka L, Niskanen M, Takala J. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002; 46: 398-404.
16. Ip M, Rainer TH, Lee N, Chan C, Chau SSL, Leung W, Leung MF, Tam TK, Antonio GE, Lui G, Lau TK, Hui DSC, Fuchs D, Renneberg R, Chan PKS. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis 2007; 59: 131-136.
17. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res 1999; 19 (3A): 1721-1728.
18. Altindag ZZ, Baydar T, Isimer A, Sahin G. Neopterin as a new biomarker for the evaluation of occupational exposure to silica. Int Arch Occup Environ Health 2003; 76: 318-322.
19. Ulker OC, Yucesoy B, Durucu M, Karakaya A. Neopterin as a marker for immune system activation in coal workers' pneumoconiosis. Toxicol Indust Health 2007; 23 (3): 155-160.
20. Leichtfried V, Putzer G, Perkofer D, Schobersberger W, Benzer A. Circadian neopterin profiles during a single 24-hour shift in anaesthetists. Pteridines 2010; 21 (2): 48-49.
21. Diamondstone LS, Tollerud DJ, Fuchs D, Wachter H, Brown LM, Maloney E, Kurman CC, Nelson DL, Blattner WA. Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population. J Clin Immunol 1994; 14: 368-374.
22. Schennach H, Murr C, Gachter E, Mayerbach P, Schönitzer D, Fuchs D. Factors influencing serum neopterin levels in a population of blood donors. Clin Chem 2002; 48 (4): 643-645.